Melanocortin 1 Receptor Agonists Based on a Bivalent, Bicyclic Peptide Framework.
J Med Chem
; 64(14): 9906-9915, 2021 07 22.
Article
em En
| MEDLINE
| ID: mdl-34197114
ABSTRACT
We have designed a new class of highly potent bivalent melanocortin receptor ligands based on the nature-derived bicyclic peptide sunflower trypsin inhibitor 1 (SFTI-1). Incorporation of melanotropin pharmacophores in each of the two turn regions of SFTI-1 resulted in substantial gains in agonist activity particularly at human melanocortin receptors 1 and 3 (hMC1R/hMC3R) compared to monovalent analogues. In in vitro binding and functional assays, the most potent molecule, compound 6, displayed low picomolar agonist activity at hMC1R (pEC50 > 10.3; EC50 < 50 pM; pKi 10.16 ± 0.04; Ki 69 ± 5 pM) and is at least 30-fold more selective for this receptor than for hMC3R, hMC4R, or hMC5R. The results are discussed in the context of structural homology models of hMCRs in complex with the developed bivalent ligands.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Peptídeos Cíclicos
/
Receptor Tipo 1 de Melanocortina
Limite:
Humans
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article